21 CFR Part 54 (Financial Disclosure by Clinical Investigators)

The obligation created by 21 CFR Part 54 belongs to the marketing applicant, not to the clinical investigator, and it is discharged at marketing-application filing, not during the trial. This is the single most useful correction for anyone arriving from a search for “FDA Form 3454”: the form is not something a site investigator files with an IND, an IRB, or an institution. It is a document the sponsor or applicant assembles from information collected from investigators and submits with the NDA, ANDA, BLA, PMA, or device application. FDA may refuse to file a marketing application that does not contain the information Part 54 requires.

Form 3454 versus Form 3455 — and the third option

Part 54 gives the applicant three ways to satisfy 21 CFR 54.4 for a covered clinical study:

• Form FDA 3454 — a certification that the listed clinical investigators did not have the financial interests or arrangements Part 54 covers. A single certification can cover all the investigators on a study who are clean.
• Form FDA 3455 — a disclosure, used where an interest exists, identifying the arrangement completely and accurately along with the steps taken to minimise the potential for bias. Disclosure is investigator-specific, so one study can carry a 3454 for most investigators and 3455s for the few with disclosable interests.
• A due-diligence certification — where the applicant acted with due diligence to obtain the required information but was unable to do so, it must certify that fact and state the reason. This is the paragraph that makes Part 54 workable for legacy trials, in-licensed programmes, and investigators who have left the field, and it is the one most often forgotten when a sponsor acquires a completed study.

All three routes share the same predicate: a list of every clinical investigator who conducted a covered clinical study. Sponsors that only begin collecting this at submission time routinely find they cannot reconstruct it for sites closed years earlier.

The thresholds that decide which form you file

Whether an interest is disclosable is set by the definitions in 21 CFR 54.2, and each threshold carries a time window that extends past the trial:

• 54.2(a) — compensation affected by the outcome: compensation to the investigator that could be higher for a favourable outcome than for an unfavourable one. There is no dollar floor; any such arrangement is disclosable.
• 54.2(b) — significant equity interest: any equity interest in a publicly traded sponsor exceeding $50,000, or any ownership interest, stock option, or other financial interest whose value cannot be readily determined through reference to public prices — which in practice means any interest in a privately held sponsor, with no threshold at all. The window runs during the time the investigator is carrying out the study and for one year following its completion.
• 54.2(c) — proprietary interest in the tested product: property or other financial interest in the product including, but not limited to, a patent, trademark, copyright, or licensing agreement. Again no dollar floor, which is why university inventors running trials on their own inventions so often trigger disclosure.
• 54.2(f) — significant payments of other sorts: payments from the sponsor to the investigator or the institution supporting the investigator’s activities with a monetary value over $25,000, exclusive of the costs of conducting the study — a grant funding other research, equipment, a retainer for ongoing consultation, honoraria — again measured during the study and for one year after completion.

The trailing year is the element most often missed. An investigator who takes a consulting retainer or an equity grant eleven months after last-patient-last-visit still generates a disclosure obligation for a study that closed the previous year.

“Clinical investigator” reaches the family

Under 21 CFR 54.2(d), a clinical investigator is a listed or identified investigator or subinvestigator who is directly involved in the treatment or evaluation of research subjects — and the definition expressly includes the investigator’s spouse and each dependent child. A financial-disclosure questionnaire that asks only about the investigator’s own holdings is not collecting what Part 54 requires.

What Part 54 is not

Part 54 is not the institutional conflict-of-interest regime research administrators know from the grants side. The PHS financial conflict-of-interest regulations at 42 CFR part 50 subpart F, as revised in 2011, apply to PHS-funded investigators, use a much lower $5,000 aggregate threshold for a significant financial interest, are administered by the institution, and require management plans and reporting to the funding agency. Part 54 involves no threshold-based management plan, no institutional determination, and no reporting during the study — it is an evidentiary filing that lets FDA weigh the reliability of the data it is being asked to rely on. An investigator can be entirely compliant with the institution’s conflict-of-interest requirements for human subjects research and still be disclosable under Part 54, and the reverse is equally possible. Note also that Part 54 attaches at marketing application rather than at IND stage, and that on the device side it reaches PMAs and those 510(k) submissions supported by clinical data.

Recordkeeping after the filing

Section 54.6 requires applicants to keep complete records of the financial interests and arrangements described in 54.4 for clinical investigators who are not full-time or part-time employees of the applicant, and to retain them for two years after the date of approval of the application. Whoever holds the records must permit an authorised FDA officer or employee to have access to, copy, and verify them. A sponsor that files its 3454s and then archives the underlying investigator questionnaires to a system it cannot retrieve from has satisfied 54.4 and failed 54.6.

Related terms

• FDA Form 3454 — the certification form itself.
• FDA Form 3455 — the disclosure form used where an interest exists.
• Significant Financial Interest (SFI) — the PHS-side concept with a different threshold and a different owner.
• NIH Financial Conflict of Interest (FCOI) Policy — the grants-side regime Part 54 is routinely confused with.
• Conflict of Interest in Human Subjects Research — the institutional review dimension.
• Investigational New Drug (IND) — the earlier stage at which Part 54 does not apply.
• FDA Medical Device Regulations: Classification, 510(k), and PMA Pathways — the device applications Part 54 reaches.

Frequently Asked Questions

Who is responsible for filing the 21 CFR Part 54 financial disclosure — the clinical investigator or the sponsor?

The obligation belongs to the marketing applicant, not to the individual clinical investigator. It is discharged at the time the marketing application is filed with FDA, not during the trial, and FDA may refuse to file an application that lacks the required financial disclosure information.

What is the difference between FDA Form 3454 and FDA Form 3455?

Form FDA 3454 is a certification that the listed investigators had none of the financial interests Part 54 covers, and a single certification can cover every investigator on a study who is clean. Form FDA 3455 is a disclosure used when an interest does exist; it is investigator-specific and must identify the arrangement completely along with the steps taken to minimise potential bias. A single study can carry a 3454 for most investigators and 3455s for the few with disclosable interests.

What counts as a “significant equity interest” under 21 CFR 54.2(b)?

For a publicly traded sponsor, it is any equity interest exceeding $50,000. For a privately held sponsor there is effectively no dollar floor at all — any ownership interest, stock option, or other financial interest whose value cannot be determined by reference to public prices is disclosable. The window covers the period the investigator carries out the study plus the year following its completion.

Is 21 CFR Part 54 the same as an institution’s conflict-of-interest policy?

No. Part 54 is an FDA evidentiary filing that lets the agency weigh the reliability of the clinical data it is being asked to rely on, with no institutional management plan and no interim reporting during the study. It is distinct from the PHS financial conflict-of-interest regulations at 42 CFR part 50 subpart F, which use a lower significant financial interest threshold and are administered by the institution rather than FDA. An investigator can be fully compliant with one regime and still be disclosable under the other.

Does the Part 54 disclosure requirement cover an investigator’s family members?

Yes. Under 21 CFR 54.2(d), the definition of “clinical investigator” expressly includes the investigator’s spouse and each dependent child, so a financial-disclosure questionnaire that asks only about the investigator’s own holdings does not collect everything Part 54 requires.

How long must Part 54 financial disclosure records be kept?

Under Section 54.6, applicants must retain complete records of the disclosed financial interests and arrangements for two years after the date the application is approved, and must permit an authorised FDA officer or employee to access, copy, and verify those records.